Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
By L. Tavazzi, A. Maggioni, Roberto Marchioli, S. Barlera, M. Franzosi, R. Latini, Donata Lucci, Gianluigi Nicolosi, Maurizio Porcu, Gianni Tognoni. The Lancet, 2008
1,017 citations recorded by the source corpus.
Subfields: Biochemistry, Cardiology and Cardiovascular Medicine, Nutrition and Dietetics
View Paper: https://www.semanticscholar.org/paper/b22d5720ce5204bf8c18c7e0eefd0dd04371b12f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biochemistry
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- Rhian M. Touyz
- T. Horwich
- Marja-Riitta Taskinen
- I. Graham
- C. Lavie
- Richard V. Milani
- J. Januzzi
In Nutrition and Dietetics
Citations in the corpus
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “may confer a small benefit in patients with chronic HF, as shown by a significant 9% relative risk reduction for mortality in the GISSI-HF RCT.(475)”
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “In contrast to patients without HF, a low TC portends a poor prognosis in HF.”
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “such as natriuretic peptides hold considerable promise (212, 213) (Section 6.”
- Omega-3 polyunsaturated fatty acids and cardiovascular diseases. (2009, background): “lished in the GISSI-HF trial (8), a large, factorial, placebo-”